Investments
10Portfolio Exits
9Partners & Customers
10Service Providers
1About BD
BD is a medical technology company that manufactures and sells a broad range of supplies, devices, and systems for use by healthcare professionals, medical research institutions, industry, and the general public.
BD Headquarter Location
1 Becton Drive
Franklin Lakes, New Jersey, 07417,
United States
201-847-6800
Expert Collections containing BD
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find BD in 4 Expert Collections, including Fortune 500 Investor list.
Fortune 500 Investor list
590 items
This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.
Conference Exhibitors
5,302 items
Medical Devices
4,399 items
https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.
Health Monitoring & Diagnostics
701 items
Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting
BD Web Traffic
BD Rank
Latest BD News
Jun 24, 2022
| Dominant Vendors Includes B. Braun Melsungen, Becton Dickinson and Company, and Codan Medizinische Gerate Among Others | SpendEdge News provided by Share this article More than 100 CPOs and 500 category managers use our insights daily SpendEdge has the fastest growth rate in number of reports and client base NEW YORK, June 24, 2022 /PRNewswire/ -- The Disposable Syringes market size is expected to grow by USD 2.63 Billion by 2026, at a Compound Annual Growth Rate (CAGR) of 6.05% during the forecast period. To know more about this market. Disposable Syringes Market Analysis Analysis of the cost and volume drivers and supply market forecasts in various regions are offered in this Disposable Syringes research report. This market intelligence report also analyzes the top supply markets, market opportunities, challenges and the critical cost drivers that can aid buyers and suppliers devise a cost-effective category management strategy. To get instant access to over 1000 market-ready procurement intelligence reports without any additional costs or commitment. Regional spend dynamism and factors impacting costs The total cost of ownership and cost-saving opportunities Supply chain margins and pricing models Competitiveness index for suppliers Supplier and buyer KPIs around the "Disposable Syringes Market." Report Metrics Leading Disposable Syringes suppliers Top Pricing Models Best Selling Procurement Research Report: Wireline Logging Services - Forecast and Analysis : The Disposable Syringes will grow at a CAGR of 5.50% during 2021-2025. Prices will increase by 3%-5% during the forecast period and suppliers will have moderate bargaining power in this market. Data Feed Management- Sourcing and Procurement Intelligence Report : The report provides a complete drill-down on global data feed management services spend outlook at a global as well as regional level. Current spend scenario, growth outlook, incremental spend, and other key information is available individually for North America, South America, Europe, Middle East and Africa, and APAC. This procurement report answers help buyers identify and shortlist the most suitable suppliers for their Disposable Syringes Market requirements following questions: Am I engaging with the right suppliers? Which KPIs should I use to evaluate my incumbent suppliers? Which supplier selection criteria are relevant for? What are the workplace computing devices category essentials in terms of SLAs and RFx? Table of Content
BD Investments
10 Investments
BD has made 10 investments. Their latest investment was in Islacare as part of their Corporate Minority on May 5, 2022.
BD Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
5/13/2022 | Corporate Minority | Islacare | Yes | 1 | ||
8/16/2017 | Series A | MedAware | $8M | Yes | 3 | |
2/23/2016 | Series D | DiabetOmics | $4.8M | Yes | 1 | |
4/6/2015 | Grant - II | |||||
11/16/2010 | Series A |
Date | 5/13/2022 | 8/16/2017 | 2/23/2016 | 4/6/2015 | 11/16/2010 |
|---|---|---|---|---|---|
Round | Corporate Minority | Series A | Series D | Grant - II | Series A |
Company | Islacare | MedAware | DiabetOmics | ||
Amount | $8M | $4.8M | |||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 1 | 3 | 1 |
BD Portfolio Exits
9 Portfolio Exits
BD has 9 portfolio exits. Their latest portfolio exit was embecta on April 01, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
4/1/2022 | Spinoff / Spinout | embecta | 2 | ||
Date | 4/1/2022 | ||||
|---|---|---|---|---|---|
Exit | Spinoff / Spinout | ||||
Companies | embecta | ||||
Valuation | |||||
Acquirer | |||||
Sources | 2 |
BD Acquisitions
27 Acquisitions
BD acquired 27 companies. Their latest acquisition was Parata on June 06, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
6/6/2022 | Acquired - II | 3 | ||||
2/1/2022 | Growth Equity | $3.02M | Acquired | 8 | ||
12/21/2021 | Other | $5.47M | Acquired | 8 | ||
12/9/2021 | Other | |||||
12/2/2021 | Debt |
Date | 6/6/2022 | 2/1/2022 | 12/21/2021 | 12/9/2021 | 12/2/2021 |
|---|---|---|---|---|---|
Investment Stage | Growth Equity | Other | Other | Debt | |
Companies | |||||
Valuation | |||||
Total Funding | $3.02M | $5.47M | |||
Note | Acquired - II | Acquired | Acquired | ||
Sources | 3 | 8 | 8 |
BD Partners & Customers
10 Partners and customers
BD has 10 strategic partners and customers. BD recently partnered with Mayo Clinic on June 6, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
6/14/2022 | Partner | United States | 1 | ||
6/9/2022 | Partner | Spain | 1 | ||
5/11/2022 | Partner | United States | `` Today 's agreement expands our long-standing partnership with BD and builds on our shared passion of making convenient blood testing accessible to all , not only in the U.S. , but also globally , '' said David Stein , chief executive officer of Babson Diagnostics . | 3 | |
5/4/2022 | Sponsored | ||||
2/8/2022 | Partner |
Date | 6/14/2022 | 6/9/2022 | 5/11/2022 | 5/4/2022 | 2/8/2022 |
|---|---|---|---|---|---|
Type | Partner | Partner | Partner | Sponsored | Partner |
Business Partner | |||||
Country | United States | Spain | United States | ||
News Snippet | `` Today 's agreement expands our long-standing partnership with BD and builds on our shared passion of making convenient blood testing accessible to all , not only in the U.S. , but also globally , '' said David Stein , chief executive officer of Babson Diagnostics . | ||||
Sources | 1 | 1 | 3 |
BD Service Providers
1 Service Provider
BD has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Acq - P2P, and Acquired - II | Investment Bank | Financial Advisor |
Service Provider | |
|---|---|
Associated Rounds | Acq - P2P, and Acquired - II |
Provider Type | Investment Bank |
Service Type | Financial Advisor |
Partnership data by VentureSource
BD Team
34 Team Members
BD has 34 team members, including current Chief Executive Officer, President, Devdatt (Dev) Kurdikar.
Name | Work History | Title | Status |
|---|---|---|---|
Tom Isett | GE Healthcare, Cytiva, and Lonza Group | Founder | Current |
Devdatt (Dev) Kurdikar | Chief Executive Officer, President | Current | |
Tom Polen | Chief Executive Officer, President | Current | |
Kevin Egesborg | President, Managing Director | Current | |
Tony Ezell | President, Chief Marketing Officer, Executive Vice President | Current |
Name | Tom Isett | Devdatt (Dev) Kurdikar | Tom Polen | Kevin Egesborg | Tony Ezell |
|---|---|---|---|---|---|
Work History | GE Healthcare, Cytiva, and Lonza Group | ||||
Title | Founder | Chief Executive Officer, President | Chief Executive Officer, President | President, Managing Director | President, Chief Marketing Officer, Executive Vice President |
Status | Current | Current | Current | Current | Current |
You May Also Like
Iaculor Injection Inc. develops low cost, more efficient needle-free injection devices that allow the delivery of powder or liquid forms of vaccines, small molecules and biologicals.
OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. Utilizing proprietary proteomic analysis, the company aims to understand patients' unique response to therapy and overcome one of the major obstacles in clinical oncology: resistance to therapy. OncoHost's host response profiling platform, PROphet®, analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient (i.e. the host) in response to a given cancer therapy. This proteomic profile is highly predictive of individual patient outcome, thus enabling personalized treatment planning. PROphet® also identifies potential drug targets, advancing the development of therapeutic strategies, as well as rationally-based combination therapies. The company was founded in 2017 and is based in Binyamina, Israel.
Ovizio develops efficient quantitative microscopy solutions for life sciences applications. The company's microscopes offer easy-to-use, label-free and non-invasive tools for real-time 3D imaging of living cells. Validated with almost every type of transparent cell culture vessel, Ovizio's devices can track cell count, cell morphology and cell viability with the highest reproducibility at a single cell level. Applicable from R&D to manufacturing processes and enabling significant cost reductions and quality improvement, Ovizio's microscopes are particularly convenient and robust for automated cell culture monitoring, analysis and quality control.
Quest Diagnostics offers medical diagnostic testing and services throughout the United States. The company has international presence, including laboratory operations in the United Kingdom, Mexico, Puerto Rico, and India.
StethoMe focuses on the development of artificial intelligence in the fields of healthcare and telemedicine. Its core product is an electronic stethoscope that coordinates with a smartphone app and specially designed algorithms - StethoMe AI.
PixCell Medical Technologies is a privately held company developing cell-based diagnostics for the point of care (POC), based on its viscoelastic focusing and microfluidics technology. The company's core technology is comprised of an analyzer and a self-contained disposable cartridge.On May 3, 2021, PixCell Medical Technologies was acquired by Soulbrain. The terms of the transaction were not disclosed.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.